Back to Search
Start Over
Successful discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis in real-world settings.
- Source :
-
Modern Rheumatology . July 2021, Vol. 31 Issue 4, p790-795. 6p. - Publication Year :
- 2021
-
Abstract
- Objectives: To analyze the proportion of successful biological disease-modifying antirheumatic drugs (bDMARDs) discontinuation and related factors in patients with rheumatoid arthritis (RA) in clinical settings. Methods: Among 1775 RA patients who started bDMARDs between 2003 and 2012, 43 patients with DAS28-ESR <3.2 at the time of bDMARD discontinuation were extracted. Patients were divided into two groups (bio-free success: BS and bio-free failure: BF groups) based on bDMARD usage and disease activity 1 year after discontinuation. We evaluated the proportion of bio-free success and assessed factors related to bio-free success. Results: Twenty-five patients (58.1%: BS group) maintained discontinuation of bDMARDs and DAS28- ESR <3.2 at 1 year after discontinuation. The median DAS28-ESR at bDMARD initiation was lower in the BS group than in the BF group (3.95 vs 5.04; p=.04). The BS group experienced a larger decrease in average glucocorticoid (GC) dose during bDMARD use than the BF group (-3.0 mg/day vs 0 mg/ day; p=.01). Conclusion: bDMARDs were discontinued without flare up of RA in 58.1% of patients with RA in clinical settings. A lower DAS28-ESR at initiation and reduction of GC dose before discontinuation of bDMARD were important factors associated with bio-free success. [ABSTRACT FROM AUTHOR]
- Subjects :
- *ANTIRHEUMATIC agents
*RHEUMATOID arthritis
*GLUCOCORTICOIDS
*PATIENTS
*ARTHRITIS
Subjects
Details
- Language :
- English
- ISSN :
- 14397595
- Volume :
- 31
- Issue :
- 4
- Database :
- Academic Search Index
- Journal :
- Modern Rheumatology
- Publication Type :
- Academic Journal
- Accession number :
- 153269707
- Full Text :
- https://doi.org/10.1080/14397595.2021.1883252